探讨尤瑞克林联合依达拉奉治疗基底动脉尖综合征(TOBS)近期临床疗效  

To investigate the recent clinical efficacy of Urechlin combined with edaravone in the treatment of basilar artery tip syndrome(TOBS)

作　　者：张小军[1] 吴云[1] 刘凤国[2] 

机构地区：[1]江苏省丹阳市人民医院ICU,江苏丹阳212300 [2]江苏省丹阳市人民医院神经内科,江苏丹阳212300

出　　处：《当代医学》2018年第5期22-24,共3页Contemporary Medicine

摘　　要：目的观察尤瑞克林联合依达拉奉治疗基底动脉尖综合征(TOBS)近期临床疗效。方法以本院2015年1月~2017年3月期间神经内科以及ICU收治的58例TOBS病例,随机将其分为观察组和对照组,每组29例。对照组患者接受常规治疗,观察组患者在对照组基础上给予尤瑞克林联合依达拉奉治疗。评价两组患者治疗后的近期临床疗效,并采用神经功能缺损评分(NIHSS)对两组患者治疗前后神经功能改善情况展开分析。结果治疗14 d后,观察组患者治疗总有效率为96.55%,对照组为86.21%,两组比较差异有统计学意义(P<0.05)。观察组患者治疗后NIHSS评分为(8.1±1.2)显著优于治疗前(12.3±2.3),且与对照组比较(9.3±1.5),差异有统计学意义(P<0.05)。结论针对基底动脉尖综合征患者可在常规综合治疗措施基础上联合使用尤瑞克林和依达拉奉,不但能显著改善患者神经功能,且治疗效果较好,值得推广。Objective To observe the recent clinical efficacy of ureikolin combined with edaravone in the treatment of basilar artery tip syndrome(TOBS). Methods 58 cases of TOBS were treated with neurology and ICU from January 2015 to March 2017, and randomly divided into observation group and control group. The patients in the control group received routine treatment, and the patients in the observation group were treated with ureiklin combined with edaravone on the control group. The clinical efficacy of the two groups was evaluated and the neurological deficit score(NIHSS) was used to analyze the neurological function of the two groups before and after treatment. Results After 14 days of treatment, the total effective rate was 96.55% in the observation group and 86.21% in the control group, the difference was statistically significant(P<0.05). The NIHSS score was(8.1±1.2) in the observation group before treatment(12.3±2.3), and the difference was statistically significant(P<0.05) compared with the control group(9.3±1.5). Conclusion Ureaclin and edaravone can be used to improve the neurological function of patients with basilar artery syndrome, and the treatment effect is good and worthy of promotion.

关 键 词：尤瑞克林 基底动脉尖综合征 依达拉奉 神经功能缺损 

分 类 号：R743.3[医药卫生—神经病学与精神病学]